Functional Jellies Special Feature
IFF Health to market Curcugen next-gen turmeric extract in hard candies and gummies
Prototyping for Curcugen’s differentiated delivery capabilities is already underway, and includes proof-of-concept formulations for non-traditional formats, including powdered drinks, oral dispersible powders, hard candies, ready-to-drink beverage shots and gummies.
A spokesperson for IFF Health said the above have already been targeted as “options for specific turn-key projects on the ingredient’s capabilities”.
Curcugen is a clean, highly concentrated and highly dispersible curcumin ingredient, boasting a wholesome turmeric base and a high (50%) curcuminoid concentration produced innovative technology. The unique profile of Curcugen is supported by the results of a new human bioavailability study showing a significant increase of bioavailability over standard extracts.
Incoming data from several ongoing clinical trials further evidences this brand’s superior functionality, said IFF Health.
“Curcugen has a great potential in key categories of food supplements and functional foods due to its versatile delivery system,” said Mark L Dewis, PhD, President of Natural Product Solutions of IFF. “We are happy to include this innovative ingredient in our portfolio of science-based natural ingredients. This enables us to expand our activities in the market for curcumin nutraceuticals in better-for-you products.”
About Curcugen
The composition of Curcugen provides a spectrum of native bioactive compounds, including the three major curcuminoids in their natural ratios, turmeric essential oils, polar resins and other natural constituents from turmeric that make its bioactive profile as robust as the rhizome itself. The standard formulation grade is palatable, disperses quickly without the need for agitation, and is suitable for use in dietary supplements, foods, and beverages. Published clinical data and safety dossiers are expected later in 2020.
“We are very excited to team up with IFF Health in the promotion of our clean-label, turmeric-derived Curcugen,” said KG Rao, President and CEO of DolCas Biotech. “DolCas and IFF Health are both strongly committed to the mission of ‘redefining how we live in and care for the resources of our world’. This mutual effort will not only meet the growing interest in curcumin throughout Europe, but support our commitment to reinvesting in the science behind our ingredients and pave the way to increased market confidence and brand exposure along the way.”
